- Home
- RVYL vs VYNE Comparison
RVYL vs VYNE Comparison
Compare RVYL & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- VYNE
- Stock Information
- Founded
- RVYL 2007
- VYNE 2003
- Country
- RVYL United States
- VYNE United States
- Employees
- RVYL N/A
- VYNE N/A
- Industry
- RVYL Professional Services
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- VYNE Health Care
- Exchange
- RVYL Nasdaq
- VYNE Nasdaq
- Market Cap
- RVYL 7.3M
- VYNE 7.9M
- IPO Year
- RVYL N/A
- VYNE 2018
- Fundamental
- Price
- RVYL $0.28
- VYNE $0.31
- Analyst Decision
- RVYL Hold
- VYNE Buy
- Analyst Count
- RVYL 1
- VYNE 2
- Target Price
- RVYL N/A
- VYNE $8.00
- AVG Volume (30 Days)
- RVYL 5.1M
- VYNE 1.7M
- Earning Date
- RVYL 11-13-2025
- VYNE 11-06-2025
- Dividend Yield
- RVYL N/A
- VYNE N/A
- EPS Growth
- RVYL N/A
- VYNE N/A
- EPS
- RVYL N/A
- VYNE N/A
- Revenue
- RVYL $48,904,000.00
- VYNE $476,000.00
- Revenue This Year
- RVYL $27.50
- VYNE N/A
- Revenue Next Year
- RVYL $35.71
- VYNE N/A
- P/E Ratio
- RVYL N/A
- VYNE N/A
- Revenue Growth
- RVYL N/A
- VYNE N/A
- 52 Week Low
- RVYL $0.25
- VYNE $0.28
- 52 Week High
- RVYL $2.35
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- RVYL 40.22
- VYNE 32.36
- Support Level
- RVYL $0.27
- VYNE $0.28
- Resistance Level
- RVYL $0.31
- VYNE $0.33
- Average True Range (ATR)
- RVYL 0.02
- VYNE 0.02
- MACD
- RVYL 0.00
- VYNE 0.03
- Stochastic Oscillator
- RVYL 17.20
- VYNE 43.45
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.